In a 41-year-old woman with positive antinuclear antibody (ANA) titer 1:640, hand, elbow, and ankle pain without synovitis, CRP 2.03 mg/dL, ESR 41 mm/hr, and a family history of rheumatoid arthritis and a brother who died from interstitial lung disease, what additional evaluations and baseline studies should be performed before starting hydroxychloroquine (Plaquenil)?

Essential Workup Before Starting Plaquenil in This Patient

Before initiating hydroxychloroquine, you must obtain a baseline ophthalmologic examination with OCT and visual field testing, assess renal function, order a baseline ECG, and critically—given the family history of fatal ILD—obtain high-resolution chest CT and pulmonary function tests to screen for subclinical interstitial lung disease. 1

Mandatory Baseline Evaluations

Ophthalmologic Assessment (Highest Priority)

Schedule ophthalmology within the first year of starting Plaquenil for baseline retinal screening 2, 1. The exam must include:

• Best corrected distance visual acuity (BCVA)
• Spectral domain optical coherence tomography (SD-OCT) - this is the most specific test
• Automated visual field testing of central 10 degrees (10-2 protocol)

This is non-negotiable as irreversible retinal damage can occur, and you need baseline comparison for future monitoring 2.

Renal Function Testing

Check serum creatinine and calculate GFR immediately 1. Subnormal glomerular filtration is a significant risk factor for hydroxychloroquine retinal toxicity and would require annual (rather than 5-year) ophthalmologic monitoring 2, 1. This also affects drug dosing and accumulation risk.

Cardiac Evaluation

Obtain a baseline ECG 1. Plaquenil can cause life-threatening cardiomyopathy, conduction abnormalities (AV block, bundle branch blocks), and QT prolongation leading to ventricular arrhythmias and torsades de pointes. Clinical monitoring for cardiomyopathy signs throughout treatment is essential.

Critical Additional Workup Given This Patient's Profile

Pulmonary Assessment (Extremely Important Here)

This patient requires immediate chest imaging and pulmonary function testing given the brother's death from ILD 3, 4. The family history of fatal ILD is a major red flag. Order:

• High-resolution chest CT (HRCT) to screen for subclinical interstitial lung disease
• Pulmonary function tests with DLCO to establish baseline lung function

Rationale: RA-ILD can precede joint symptoms 5, and this patient has multiple risk factors: elevated inflammatory markers (ESR 41, CRP 2.03), high-titer ANA (1:640), and critically, a first-degree relative who died from ILD 6, 3. Male sex, older age, smoking history (if present), and rheumatoid nodules increase RA-ILD risk 3. Early detection is crucial as RA-ILD significantly impairs treatment outcomes and increases mortality 7.

Expanded Serologic Panel

Beyond the ANA you already have, obtain:

• Anti-CCP antibodies - strongly associated with RA-ILD risk 6, 3
• Rheumatoid factor (RF) - elevated in RA-ILD 6, 8
• Anti-ENA panel (anti-Ro/SSA, anti-La/SSB) - to evaluate for overlap syndromes, especially given high ANA titer 8
• Complete metabolic panel - baseline liver and kidney function
• Complete blood count - ANA-positive RA patients tend to have lower hemoglobin and platelets 8

The high ANA titer (1:640) without synovitis raises concern for overlap features or early systemic disease 9, 10. The absence of synovitis despite joint pain is atypical and warrants broader autoimmune evaluation.

Baseline Inflammatory Markers

Document baseline CRP and ESR (already done - CRP 2.03, ESR 41), as these will guide treatment response monitoring.

Dosing Considerations

Do not exceed 5 mg/kg/day (base weight) of hydroxychloroquine 1. For a typical dose, this translates to 200-400 mg daily (not exceeding 400 mg). Calculate based on actual body weight. Doses above this threshold significantly increase retinopathy risk 2, 1.

Monitoring Schedule After Initiation

• Ophthalmology: Annual exams can be deferred until 5 years if no risk factors, BUT this patient may have risk factors (check renal function first) 2, 1
• Clinical assessment: Monitor for muscle weakness, cardiac symptoms, and respiratory symptoms at each visit 1
• Pulmonary: Given family ILD history, consider repeat HRCT and PFTs at 6-12 months even if baseline is normal

Critical Pitfalls to Avoid

1. Do not start Plaquenil without baseline ophthalmology - you lose the ability to distinguish pre-existing from drug-induced retinal changes 2
2. Do not overlook the ILD family history - this patient needs pulmonary screening regardless of current respiratory symptoms 3, 5
3. Do not dose by standard protocols without weight-based calculation - overdosing dramatically increases toxicity risk 1
4. Do not ignore the high ANA without synovitis - this atypical presentation may indicate evolving overlap syndrome requiring closer monitoring 9, 10